Prostate cancer is the second-most common cancer in men. A new study from Thomas Jefferson University uncovered a new ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

A newly uncovered mechanism thought to be a weakness of prostate cancer cells could inspire a new and improved targeted treatment for the disease. International research led by Flinders University in ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...